← Back to Screener
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)
Price$524.76
Favorite Metrics
Price vs S&P 500 (26W)14.70%
Price vs S&P 500 (4W)11.50%
Market Capitalization$11.90B
All Metrics
Book Value / Share (Quarterly)$26.39
P/TBV (Annual)22.22x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-8.45
Price vs S&P 500 (YTD)-13.59%
Gross Margin (TTM)94.14%
Net Profit Margin (TTM)-30.08%
EPS (TTM)$-12.85
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-12.85
EPS (Annual)$-12.85
ROI (Annual)-30.58%
Gross Margin (Annual)94.14%
Net Profit Margin (5Y Avg)-12793.16%
Cash / Share (Quarterly)$43.06
Revenue Growth QoQ (YoY)210.77%
ROA (Last FY)-22.89%
Revenue Growth TTM (YoY)432.05%
EBITD / Share (TTM)$-13.45
ROE (5Y Avg)-94.94%
Operating Margin (TTM)-31.60%
Cash Flow / Share (Annual)$-8.45
P/B Ratio19.74x
P/B Ratio (Quarterly)21.94x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)12.56x
Net Interest Coverage (TTM)-163.11x
ROA (TTM)-24.88%
EV / EBITDA (TTM)726.46x
EPS Incl Extra (Annual)$-12.85
Current Ratio (Annual)4.01x
Quick Ratio (Quarterly)3.62x
3-Month Avg Trading Volume0.35M
52-Week Price Return60.89%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$26.06
P/S Ratio (Annual)12.41x
Asset Turnover (Annual)0.76x
52-Week High$615.00
Operating Margin (5Y Avg)-12410.94%
EPS Excl Extra (Annual)$-12.85
CapEx CAGR (5Y)60.06%
Tangible BV CAGR (5Y)1.61%
26-Week Price Return18.68%
Quick Ratio (Annual)3.62x
13-Week Price Return1.58%
Total Debt / Equity (Annual)0.56x
Current Ratio (Quarterly)4.01x
Enterprise Value$12,037.396
Asset Turnover (TTM)0.83x
Book Value / Share Growth (5Y)11.25%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-30.08%
Cash / Share (Annual)$43.06
3-Month Return Std Dev45.16%
Net Income / Employee (TTM)$-0
ROE (Last FY)-47.83%
Net Interest Coverage (Annual)-229.75x
EPS Basic Excl Extra (Annual)$-12.85
P/FCF (TTM)156.54x
Receivables Turnover (TTM)10.18x
Total Debt / Equity (Quarterly)0.56x
EPS Incl Extra (TTM)$-12.85
Receivables Turnover (Annual)10.18x
ROI (TTM)-32.47%
P/S Ratio (TTM)12.41x
Pretax Margin (5Y Avg)-12793.16%
Revenue / Share (Annual)$42.72
Tangible BV / Share (Annual)$26.06
Price vs S&P 500 (52W)31.06%
Year-to-Date Return-10.95%
5-Day Price Return-1.09%
EPS Normalized (Annual)$-12.85
ROA (5Y Avg)-59.17%
Net Profit Margin (Annual)-30.08%
Month-to-Date Return-0.93%
Cash Flow / Share (TTM)$-19.21
EBITD / Share (Annual)$-13.45
Operating Margin (Annual)-31.60%
LT Debt / Equity (Annual)0.56x
ROI (5Y Avg)-79.76%
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$-12.85
P/TBV (Quarterly)22.22x
P/B Ratio (Annual)21.94x
Inventory Turnover (TTM)1.03x
Pretax Margin (TTM)-30.08%
Book Value / Share (Annual)$26.39
Price vs S&P 500 (13W)0.89%
Beta-1.12x
P/FCF (Annual)478.34x
Revenue / Share (TTM)$41.76
ROE (TTM)-43.76%
52-Week Low$265.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.08
4.09
4.09
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MDGLMadrigal Pharmaceuticals, Inc. Common Stock | 12.41x | 432.05% | 94.14% | — | $524.76 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease with significant unmet medical need. Its lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor beta agonist designed to address the underlying causes of MASH and prevent progression to cirrhosis and liver failure.